FKH’s Health Datapalooza IV Panel
June 4, 1:30-3:30
Health Datapalooza is the premier national conference on liberating health data to achieve better health outcomes. The event, organized by the Health Data Consortium, showcases in real-time the most innovative tools and services that use Big Data to improve healthcare.
FKH was proud to be a partner and sponsor at Health Datapalooza IV, where FKH Chairman and Health Datapalooza Planning Committee Member Marcia Kean organized a panel on, “Illuminating Disease at the Speed of Light: How Big Data Is Accelerating Biomedical Research and Development.” As the biomedical field explodes with big-data-related R&D activity, four thought leaders demonstrated their online tools to:
- Turn large volumes of complex data into actionable information.
- Use high-speed genome profiling for quick molecularly-based diagnoses of “mystery” diseases.
- Drive a statewide point-of-care quality monitoring program being used by physicians in routine clinical practice, in which data are banked; used to determine important questions for research; and then picked up by a national clinical trials network and transitioned into clinical trials.
- Enable collection and aggregation of data on multiple sclerosis (MS), drive collaborative efforts to analyze markers of MS origins, and discover new therapeutics.
- Amy P. Abernethy, MD
Director, Center for Learning Healthcare, Duke Clinical Research Institute
Amy P. Abernethy, MD, a medical oncologist and palliative care physician, is director of the Duke Center for Learning Health Care (CLHC) in the Duke Clinical Research Institute, and director of the Duke Cancer Care Research Program (DCCRP) in the Duke Cancer Institute. An internationally recognized expert in health services research, cancer informatics, and delivery in patient-centered cancer care, she directs a prolific research program (CLHC/DCCRP) which conducts patient-centered clinical trials, analyses, and policy studies.Dr. Abernethy participates integrally in current high-level national and international discussions about reforming the evidence development system, presenting a model for a rapid learning cancer clinic that coordinates clinical and research functions to better serve patients’ needs in an evidence-driven, cost-effective, and patient-centered manner.
- Michael Cantor, M.D., MA, FACP
Senior Director, Information Strategy and Analytics, World Research and Development, Pfizer
Michael Cantor’s work focuses on the secondary use of clinical data, personalized medicine, and automated methods for pharmacovigilance. At Pfizer, he is leading the PEER (Pfizer Externally Enabled Research) initiative, which aims to partner with academic medical centers to perform observational studies using data from electronic medical record (EMR) systems. He also helped lead Pfizer’s efforts with the e-Health Initiative’s Connecting Communities for Drug Safety, a partnership between academia and the pharmaceutical industry exploring the use of EMRs for pharmacovigilance. He is a member of Pfizer’s Personalized Medicine SMART team, and helped organize Pfizer’s Personalized Medicine symposium. Current projects also involve mobile technologies for healthcare and text mining for competitive intelligence.
- Robert McBurney, Ph.D.
CEO, Accelerated Cure Project for Multiple Sclerosis
Robert McBurney joined the Accelerated Cure Project for Multiple Sclerosis as its Chief Executive in mid-2011 because he was compelled by the organization’s novel approach to catalyzing innovation in research towards a cure for MS.He is a neuroscientist by training and has over 35 years of experience in biomedical research and in the management of research-based biotech companies. During the past 25 years, Robert has either founded or played leading roles in biotech companies in the US and in Europe, including Optimal Medicine, Theragenetics, BG Medicine, Differential Proteomics, CeNeS Pharmaceuticals, and Cambridge NeuroScience.
- Dietrich A. Stephan, Ph.D.
Founder, President and CEO, and Member of the Board of Directors, SV Bio
Dr. Stephan, the founder, president and CEO of SV Bio, is a geneticist, entrepreneur, and recognized leader in the field of personalized medicine. Prior to SV Bio, he was executive director of the Gene Partnership at Harvard Medical School and Children’s Hospital Boston, where he architected and capitalized a groundbreaking genomic medicine pediatric program, as well as a genomic cancer program at Fox Chase Cancer Center.In 2006, Dr. Stephan founded Navigenics, Inc., a pioneering consumer genomics company. Prior to that, he served as part of the leadership team of the Translational Genomics Research Institute (TGen), building it into one of the largest free-standing research institutes in the world.Dr. Stephan is on the board of directors of several organizations, including the Personalized Medicine Coalition, and continues to found biotechnology companies, including Aueon, Amnestix, and DiaVacs.